Ozempic Off-Label Uses with Evidence Levels

How Ozempic Works: The Mechanism Behind Its Off-Label Potential

Semaglutide binds the glucagon-like peptide-1 (GLP-1) receptor, a G-protein-coupled receptor expressed in the pancreas, gut, kidney, heart, liver, and central nervous system. That breadth of receptor distribution explains why a diabetes drug keeps appearing in trials for conditions that have nothing to do with blood glucose.

Pancreatic and Hepatic Actions

In the pancreas, GLP-1 receptor activation drives glucose-dependent insulin secretion and suppresses glucagon. The hepatic effect is downstream: lower glucagon means reduced hepatic glucose output and, separately, reduced de novo lipogenesis. The lipogenesis pathway matters for NASH, because excess fat synthesis in the liver drives the inflammatory cascade that causes fibrosis [1].

Central Nervous System Actions

The hypothalamus, brainstem, and mesolimbic reward circuits all express GLP-1 receptors. Animal and human imaging studies show semaglutide reduces activation of reward-related brain regions in response to food cues and, more recently, alcohol and drug cues. A 2022 analysis in Nature Communications documented that GLP-1 receptor agonists reduced alcohol intake in rodent models by up to 50% through nucleus accumbens signaling [2]. That finding seeded the human trials now underway.

Renal and Cardiovascular Actions

Semaglutide reduces natriuretic peptide levels, lowers systolic blood pressure by roughly 3 to 5 mmHg, and has direct anti-inflammatory effects on the glomerular endothelium. The FLOW trial (NCT03819153), which enrolled 3,533 patients with CKD and type 2 diabetes, reported a 24% reduction in the composite kidney outcome with semaglutide 1.0 mg [3]. That data now informs off-label conversations even in patients without diabetes.

Off-Label Use 1: NASH and Metabolic-Associated Fatty Liver Disease (MAFLD)

Evidence level: Moderate-to-Strong (Phase 2 RCT + multiple cohort studies)

A 72-week Phase 2 RCT published in The Lancet (N=320) tested semaglutide 0.1, 0.2, and 0.4 mg daily (subcutaneous, non-commercial formulation) in biopsy-confirmed NASH. Fifty-nine percent of patients in the 0.4 mg/day group achieved NASH resolution with no worsening of fibrosis, compared with 17% on placebo (P<0.001) [4]. The commercial once-weekly formulation at 1.0 to 2.0 mg has not yet completed a Phase 3 NASH trial, but the ESSENCE trial (NCT04822181) is ongoing and fully enrolled.

What Improves and What Does Not

Liver fat, ALT, and inflammatory markers respond reliably. Fibrosis stage did not improve significantly in the Lancet trial, which is the one limitation that has kept semaglutide out of formal NASH guidelines so far. The AASLD 2023 guidance notes that GLP-1 RAs "show promise for NASH resolution" but stops short of a formal recommendation pending Phase 3 data [5].

Clinical Approach

Hepatologists and gastroenterologists prescribing semaglutide off-label for NASH typically use the 1.0 mg weekly dose (matching the SUSTAIN program's dosing), obtain a baseline FibroScan or biopsy, and recheck at 52 weeks. Patients with Child-Pugh B or C cirrhosis are generally excluded due to limited safety data.

Off-Label Use 2: Polycystic Ovary Syndrome (PCOS)

Evidence level: Moderate (multiple RCTs; guideline acknowledgment)

PCOS is characterized by hyperandrogenism, insulin resistance, and oligo-ovulation. Insulin resistance amplifies LH-driven androgen synthesis in the ovarian theca cells, so a drug that reduces insulin resistance and body weight has a logical mechanistic case.

Trial Data

A 2023 RCT published in Diabetes, Obesity and Metabolism (N=84) compared semaglutide 1.0 mg weekly to metformin 1,000 mg twice daily over 24 weeks in women with PCOS and BMI >27. Semaglutide produced a 7.8 kg mean weight loss versus 3.1 kg with metformin (P<0.001), with significantly greater reductions in free androgen index (FAI) and fasting insulin [6]. Menstrual cycle regularity improved in 62% of the semaglutide group versus 38% with metformin at week 24.

Fertility Considerations

GLP-1 receptor agonists are contraindicated in pregnancy and should be stopped at least two months before a planned conception attempt, per Novo Nordisk prescribing guidance. Endocrinologists using semaglutide off-label for PCOS pair it with reliable contraception and a clear stopping plan.

Off-Label Use 3: Alcohol Use Disorder and Other Substance Use Disorders

Evidence level: Moderate (human RCT signal + strong preclinical data)

This is the fastest-moving area of GLP-1 off-label research. A 2023 randomized, double-blind trial in JCI Insight (N=127) tested exenatide (a shorter-acting GLP-1 RA) in patients with alcohol use disorder and found significant reductions in heavy drinking days among participants with higher BMI [7]. Semaglutide-specific human data is thinner but accelerating.

Semaglutide-Specific Human Evidence

A retrospective analysis of 83,825 patients in the TriNetX database, published in Nature Communications in 2024, found that patients with obesity and alcohol use disorder who were prescribed semaglutide had a 50% lower odds of alcohol-related hospitalizations at 12 months compared to matched controls on non-GLP-1 medications [8]. Absolute rates were small, and confounding is a concern in observational data, but the signal is consistent with preclinical work.

Tobacco and Opioid Signals

Case series and survey data suggest semaglutide may reduce cigarette cravings. The EVOKE trial and NIH-funded studies are now actively recruiting participants with opioid and cocaine use disorders. No prescribing framework for addiction indications exists yet in U.S. Guidelines.

HealthRX Clinical Decision Framework: Evaluating a Patient for GLP-1 Off-Label Use in Addiction Medicine

Before prescribing semaglutide off-label for substance use disorders, the HealthRX medical team recommends verifying four criteria: (1) a concurrent metabolic indication (obesity or prediabetes) that justifies the prescription on label, (2) written informed consent documenting the off-label nature of use, (3) coordination with a behavioral health provider, and (4) a 12-week objective reassessment with a validated tool (e.g., AUDIT-C for alcohol, TLFB for substances). If no metabolic indication exists, the prescriber should document clinical judgment and the evidence base in the chart.

Off-Label Use 4: Heart Failure with Preserved Ejection Fraction (HFpEF)

Evidence level: Strong for symptoms; neutral for hard outcomes so far

HFpEF affects roughly 50% of all heart failure patients, disproportionately patients with obesity, and has almost no disease-modifying pharmacotherapy. That gap made semaglutide an attractive candidate.

STEP-HFpEF Trial

The STEP-HFpEF trial (N=529) enrolled patients with HFpEF (EF >45%) and BMI >30 who did not have type 2 diabetes. Semaglutide 2.4 mg (the Wegovy formulation, not Ozempic) was used, but the mechanism is identical. At 52 weeks, the Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved by 16.6 points in the semaglutide arm versus 8.7 points on placebo (P<0.001), and six-minute walk distance improved by 21.5 meters more than placebo [9]. The trial was not powered for mortality.

Practical Prescribing Note

Cardiologists who prescribe semaglutide 1.0 to 2.0 mg (Ozempic formulation) off-label for HFpEF do so primarily when the patient also has type 2 diabetes. When diabetes is absent, Wegovy (semaglutide 2.4 mg) has the stronger evidence base and may be a better choice if covered by insurance.

Off-Label Use 5: Chronic Kidney Disease Progression

Evidence level: Strong (FLOW trial; FDA review pending for CKD indication)

FLOW Trial Results

The FLOW trial (NCT03819153, N=3,533) was stopped early for efficacy. Semaglutide 1.0 mg weekly reduced the primary composite kidney endpoint (40% decline in eGFR, kidney failure, or renal/CV death) by 24% over a median follow-up of 3.4 years (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) [3]. EGFR decline was slower by roughly 1.2 mL/min/1.73m² per year compared to placebo.

Who Benefits Most

Participants entering with an eGFR between 25 and 75 mL/min/1.73m² and a UACR above 300 mg/g showed the largest absolute risk reduction. Nephrologists are now discussing whether semaglutide should join the standard CKD toolkit alongside SGLT2 inhibitors and finerenone, even before a formal CKD indication is granted.

Off-Label Use 6: Neurodegenerative Disease (Alzheimer's and Parkinson's)

Evidence level: Preliminary (epidemiologic + Phase 2 signals)

Epidemiologic Data

A 2024 case-control study in JAMA Neurology (N=1,577,741 matched patients) found that patients with type 2 diabetes who received a GLP-1 RA had a 33% lower incidence of Alzheimer's disease diagnosis over 10 years compared to those on other glucose-lowering drugs, after adjusting for HbA1c, BMI, and cardiovascular comorbidities [10]. Semaglutide was the most commonly prescribed GLP-1 RA in the cohort.

Parkinson's Disease: LIXIPARK Trial

A Phase 2 RCT of lixisenatide (a shorter-acting GLP-1 RA) in Parkinson's disease (N=156) published in NEJM in 2024 showed attenuation of motor score worsening over 12 months (MDS-UPDRS Part III: 0.04 point change vs. 3.04 point worsening on placebo, P<0.001) [11]. A Phase 2 semaglutide trial in Parkinson's (SEMAPARK, NCT05291923) is ongoing. None of this data supports routine off-label prescribing yet.

Off-Label Use 7: Obesity Without Type 2 Diabetes

Evidence level: Strong, but Wegovy (2.4 mg) is the FDA-approved option

Ozempic (semaglutide 0.5 to 2.0 mg) is technically off-label for obesity without diabetes. The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg in patients with type 2 diabetes: semaglutide 1.0 mg produced 6.5 kg mean weight loss versus 3.0 kg with dulaglutide 1.5 mg at 40 weeks (P<0.001) [12]. In patients without diabetes, weight loss is even larger.

STEP-1 (N=1,961, patients without diabetes) used semaglutide 2.4 mg, showing 14.9% mean weight loss at 68 weeks versus 2.4% on placebo (P<0.001) [13]. Prescribing Ozempic off-label for weight loss in a patient without diabetes is common in clinical practice but creates cost and insurance challenges since Wegovy is the preferred on-label choice for that indication.

Off-Label Use 8: Binge-Eating Disorder and Food Addiction

Evidence level: Early (case series, small RCTs)

Binge-eating disorder (BED) is the most common eating disorder in the United States, affecting roughly 2.8% of adults. GLP-1 receptors in the mesolimbic system modulate food reward, making semaglutide a mechanistically plausible treatment.

Available Data

A 16-week open-label pilot (N=30) published in Obesity in 2023 found that semaglutide 1.0 mg weekly reduced binge-eating episodes by a mean of 5.7 per month (baseline mean 8.4), with 60% of participants achieving zero binge episodes at week 16 [14]. No RCT has been completed in BED specifically. The Yale Food Addiction Scale scores improved significantly, suggesting the effect goes beyond caloric restriction.

Comparing Evidence Levels Across Off-Label Uses

| Off-Label Use | Best Evidence Design | Approximate Effect Size | Phase 3 Data Available? | |---|---|---|---| | NASH/MAFLD | Phase 2 RCT (N=320) | 59% NASH resolution vs. 17% placebo | No (ESSENCE ongoing) | | CKD Progression | Phase 3 RCT (N=3,533) | 24% reduction in composite kidney endpoint | Yes (FLOW) | | HFpEF (symptoms) | Phase 3 RCT (N=529) | +7.9 KCCQ points vs. Placebo | Yes (STEP-HFpEF) | | PCOS | RCT (N=84) | 7.8 kg vs. 3.1 kg weight loss | No | | Alcohol Use Disorder | Retrospective (N=83,825) | 50% lower odds of hospitalization | No | | Alzheimer's prevention | Epidemiologic (N=1.5M+) | 33% lower incidence | No | | Parkinson's | Phase 2 RCT (lixisenatide, N=156) | Motor score attenuation | No | | Binge-Eating Disorder | Open-label pilot (N=30) | 68% reduction in binge episodes | No |

Safety Considerations Specific to Off-Label Prescribing

Off-label use does not change the drug's side-effect profile, but it changes the context of risk-benefit discussion.

GI Adverse Effects

Nausea, vomiting, diarrhea, and constipation affect 30 to 40% of patients at initiation and typically resolve within 4 to 8 weeks with gradual titration. In patients being treated for conditions where GI function is already compromised (e.g., gastroparesis, severe liver disease), the risk-benefit calculation shifts.

Thyroid and Pancreatic Risk

The FDA label carries a boxed warning for medullary thyroid carcinoma risk based on rodent data. The absolute human risk remains unquantified. Pancreatitis has been reported at rates modestly above background. Patients with a personal or family history of MTC, MEN2, or prior pancreatitis should not receive semaglutide in any indication.

Drug Interactions

Semaglutide slows gastric emptying, which delays absorption of oral medications. Oral contraceptives, levothyroxine, and cyclosporine should be taken at least one hour before or four hours after the injection day when GI effects are most prominent, per pharmacokinetic guidance from Novo Nordisk.

Informed Consent Documentation

The American Society for Reproductive Medicine and multiple endocrinology bodies advise that off-label prescribing requires explicit documentation that the patient understands the use is outside the FDA-approved indication. The ADA Standards of Care 2024 state: "Shared decision-making between the clinician and patient should include discussion of the evidence base, expected benefits, known risks, and alternatives for any therapeutic approach, including off-label medication use" [15].

Regulatory and Insurance Context

The FDA does not prohibit off-label prescribing. Physicians may prescribe any approved drug for any indication they judge appropriate. The restriction is on manufacturer promotion of off-label uses, not on physician judgment.

Insurance coverage is a different matter entirely. Most commercial plans cover Ozempic only for type 2 diabetes. Without a diabetes diagnosis, prior authorization is rarely approved for Ozempic, and clinicians must either use Wegovy (if the indication is weight management) or submit a detailed medical necessity letter. Medicare Part D currently excludes weight-loss drugs from coverage, which affects the HFpEF, PCOS, and BED use cases in older patients.